UMB Bank n.a. Has $52.55 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

UMB Bank n.a. decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 316,859 shares of the company's stock after selling 2,541 shares during the quarter. Johnson & Johnson makes up 0.9% of UMB Bank n.a.'s holdings, making the stock its 27th largest holding. UMB Bank n.a.'s holdings in Johnson & Johnson were worth $52,548,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LexAurum Advisors LLC grew its stake in Johnson & Johnson by 0.4% in the first quarter. LexAurum Advisors LLC now owns 55,860 shares of the company's stock valued at $9,264,000 after purchasing an additional 205 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Johnson & Johnson by 47.4% in the 1st quarter. Sivia Capital Partners LLC now owns 5,171 shares of the company's stock worth $858,000 after purchasing an additional 1,663 shares in the last quarter. Perkins Coie Trust Co boosted its holdings in Johnson & Johnson by 2.9% in the first quarter. Perkins Coie Trust Co now owns 3,283 shares of the company's stock worth $544,000 after acquiring an additional 94 shares in the last quarter. Joule Financial LLC boosted its stake in Johnson & Johnson by 4.1% in the 1st quarter. Joule Financial LLC now owns 2,391 shares of the company's stock worth $397,000 after purchasing an additional 95 shares in the last quarter. Finally, Intergy Private Wealth LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $339,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Raymond James lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Barclays lowered their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.16 on Monday, reaching $155.19. The company's stock had a trading volume of 5,318,668 shares, compared to its average volume of 7,939,527. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's 50-day moving average is $153.59 and its two-hundred day moving average is $153.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $373.40 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.